logo
welcome
Reuters

Reuters

Gilead 3rd-quarter results beat Wall Street estimates, raises outlook

Reuters
Summary
Nutrition label

75% Informative

Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations.

Third-quarter sales of HIV drug Biktarvy rose 13% to $3.5 billion .

Sales of COVID-19 treatment Veklury rose 9% .

Company raised its product sales forecast to a range of $27.8 billion to $28.1 billion .

VR Score

88

Informative language

98

Neutral language

1

Article tone

formal

Language

English

Language complexity

32

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links